The Experts below are selected from a list of 8469 Experts worldwide ranked by ideXlab platform

Janice M Reichert - One of the best experts on this subject based on the ideXlab platform.

  • Antibody Engineering & therapeutics, the annual meeting of the Antibody society December 7–10, 2015, San Diego, CA, USA
    mAbs, 2016
    Co-Authors: Matthias Pauthner, Thierry Wurch, Janice M Reichert, Jenny Yeung, Chris Ullman, Joost Bakker, Fridtjof Lund-johansen, Andrew Bradbury, Paul Carter, Joost P.m. Melis
    Abstract:

    The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015. The latest innovations and advances in Antibody research and development were discussed, covering a myriad of Antibody-related topics by more than 100 speakers, who were carefully selected by The Antibody Society. As a prelude, attendees could join the pre-conference training course focusing, among others, on the Engineering and enhancement of antibodies and Antibody-like scaffolds, bispecific Antibody Engineering and adaptation to generate chimeric antigen receptor constructs. The main event covered 4 d of scientific sessions that included Antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in Antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, Antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, building comprehensive IgVH-gene repertoires through discovering, confirming and cataloging new germline IgVH genes, and overcoming resistance to clinical immunotherapy. The Antibody Society's special session focused on "Antibodies to watch" in 2016. Another special session put the spotlight on the limitations of the new definitions for the assignment of Antibody international nonproprietary names introduced by the World Health Organization. The convention concluded with workshops on computational Antibody design and on the promise and challenges of using next-generation sequencing for Antibody discovery and Engineering from synthetic and in vivo libraries.

  • Antibody Engineering and Therapeutics Conference: The Annual Meeting of the Antibody Society, December 8–12, 2013, Huntington Beach, CA
    mAbs, 2014
    Co-Authors: Juan Almagro, Gary L. Gilliland, Janice M Reichert, Matthias Pauthner, Felix Breden, Jamie K. Scott, Devin Sok, Gustavo Helguera, Raiees Andrabi, Robert Mabry
    Abstract:

    The 24th Antibody Engineering & Therapeutics meeting brought together a broad range of participants who were updated on the latest advances in Antibody research and development. Organized by IBC Life Sciences, the gathering is the annual meeting of The Antibody Society, which serves as the scientific sponsor. Preconference workshops on 3D modeling and delineation of clonal lineages were featured, and the conference included sessions on a wide variety of topics relevant to researchers, including systems biology; Antibody deep sequencing and repertoires; the effects of Antibody gene variation and usage on Antibody response; directed evolution; knowledge-based design; antibodies in a complex environment; polyreactive antibodies and polyspecificity; the interface between Antibody therapy and cellular immunity in cancer; antibodies in cardiometabolic medicine; Antibody pharmacokinetics, distribution and off-target toxicity; optimizing Antibody formats for immunotherapy; polyclonals, oligoclonals and bispecifics; Antibody discovery platforms; and Antibody-drug conjugates.

  • Antibody Engineering and therapeutics conference the annual meeting of the Antibody society december 8 12 2013 huntington beach ca
    mAbs, 2013
    Co-Authors: Juan Almagro, Gary L. Gilliland, Janice M Reichert, Matthias Pauthner, Felix Breden, Jamie K. Scott, Devin Sok, Gustavo Helguera, Raiees Andrabi, Robert Mabry
    Abstract:

    The 24th Antibody Engineering & Therapeutics meeting brought together a broad range of participants who were updated on the latest advances in Antibody research and development. Organized by IBC Life Sciences, the gathering is the annual meeting of The Antibody Society, which serves as the scientific sponsor. Preconference workshops on 3D modeling and delineation of clonal lineages were featured, and the conference included sessions on a wide variety of topics relevant to researchers, including systems biology; Antibody deep sequencing and repertoires; the effects of Antibody gene variation and usage on Antibody response; directed evolution; knowledge-based design; antibodies in a complex environment; polyreactive antibodies and polyspecificity; the interface between Antibody therapy and cellular immunity in cancer; antibodies in cardiometabolic medicine; Antibody pharmacokinetics, distribution and off-target toxicity; optimizing Antibody formats for immunotherapy; polyclonals, oligoclonals and bispecifics; Antibody discovery platforms; and Antibody-drug conjugates.

  • ibc s 21 st annual Antibody Engineering and 8 th annual Antibody therapeutics international conferences and 2010 annual meeting of the Antibody society
    mAbs, 2013
    Co-Authors: Samantha O Arnett, Jeanluc Teillaud, Thierry Wurch, Janice M Reichert, Cameron Dunlop, Michael Huber
    Abstract:

    The 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences, and the 2012 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 3–6, 2012 in San Diego, CA. The meeting drew over 800 participants who attended sessions on a wide variety of topics relevant to Antibody research and development. As a prelude to the main events, a pre-conference workshop held on December 2, 2012 focused on intellectual property issues that impact Antibody Engineering. The Antibody Engineering Conference was composed of six sessions held December 3–5, 2012: (1) From Receptor Biology to Therapy; (2) Antibodies in a Complex Environment; (3) Antibody Targeted CNS Therapy: Beyond the Blood Brain Barrier; (4) Deep Sequencing in B Cell Biology and Antibody Libraries; (5) Systems Medicine in the Development of Antibody Therapies/Systematic Validation of Novel Antibody Targets; and (6...

  • IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.
    mAbs, 2012
    Co-Authors: John Marquardt, Janice M Reichert, Andrew Bradbury, Richard H J Begent, James S. Huston, Kerry A. Chester, Jamie K. Scott, Trudi Veldman, Philip E. Thorpe, Louis M. Weiner
    Abstract:

    Now in its 23rd and 10th years, respectively, the Antibody Engineering and Antibody Therapeutics conferences are the Annual Meeting of The Antibody Society. The scientific program covers the full spectrum of challenges in Antibody research and development from basic science through clinical development. In this preview of the conferences, the chairs provide their thoughts on sessions that will allow participants to track emerging trends in (1) the development of next-generation immunomodulatory antibodies; (2) the complexity of the environment in which antibodies must function; (3) Antibody-targeted central nervous system (CNS) therapies that cross the blood brain barrier; (4) the extension of Antibody half-life for improved efficacy and pharmacokinetics (PK)/pharmacodynamics (PD); and (5) the application of next generation DNA sequencing to accelerate Antibody research. A pre-conference workshop on Sunday, December 2, 2012 will update participants on recent intellectual property (IP) law changes that affect Antibody research, including biosimilar legislation, the America Invents Act and recent court cases. Keynote presentations will be given by Andreas Plückthun (University of Zürich), who will speak on Engineering receptor ligands with powerful cellular responses; Gregory Friberg (Amgen Inc.), who will provide clinical updates of bispecific antibodies; James D. Marks (University of California, San Francisco), who will discuss a systems approach to generating tumor targeting antibodies; Dario Neri (Swiss Federal Institute of Technology Zürich), who will speak about delivering immune modulators at the sites of disease; William M. Pardridge (University of California, Los Angeles), who will discuss delivery across the blood-brain barrier; and Peter Senter (Seattle Genetics, Inc.), who will present his vision for the future of Antibody-drug conjugates. For more information on these meetings or to register to attend, please visit www.IBCLifeSciences.com/AntibodyEng or call 800-390-4078. Members of The Antibody Society and mAbs journal subscribers receive a 20% discount for meeting registration. To obtain this discount, email kdostie@ibcusa.com. mAbs is the official therapeutics journal of The Antibody Society and offers a discounted subscription to Society members for $49.

Jamie K. Scott - One of the best experts on this subject based on the ideXlab platform.

  • Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    mAbs, 2015
    Co-Authors: Paul W. H. I. Parren, Andrew Bradbury, James W Larrick, James S. Huston, Kerry A. Chester, Dennis R. Burton, Paul J Carter, Trudi Veldman, Mark R Alfenito, Jamie K. Scott
    Abstract:

    Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, will be held in San Diego, CA in early December 2015. In this meeting preview, the chairs provide their thoughts on the importance of their session topics, which include Antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in Antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, Antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, overcoming resistance to clinical immunotherapy, and building comprehensive IGVH-gene repertoires through discovering, confirming and cataloging new germline IGVH genes. The Antibody Society's special session will focus on "Antibodies to watch" in 2016, which are a subset of the nearly 50 antibodies currently in Phase 3 clinical studies. Featuring over 100 speakers in total, the meeting will commence with keynote presentations by Erica Ollmann Saphire (The Scripps Research Institute), Wayne A. Marasco (Dana-Farber Cancer Institute/Harvard Medical School), Joe W. Gray (Oregon Health & Science University), and Anna M. Wu (University of California Los Angeles), and it will conclude with workshops on the promise and challenges of using next-generation sequencing for Antibody discovery and Engineering from synthetic and in vivo libraries and on computational Antibody design.

  • Antibody Engineering & Therapeutics 2016: The Antibody Society's Annual Meeting, December 11-15, 2016, San Diego, CA
    mAbs, 2015
    Co-Authors: James W Larrick, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Dennis R. Burton, Jamie K. Scott, Mark R Alfenito, Cynthia A. Lemere, Anne Messer, Paul Carter
    Abstract:

    Antibody Engineering & Therapeutics, the largest meeting devoted to Antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and future Antibody therapeutics development. Session topics include bispecifics and designer polyclonal antibodies; antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy; antibodies for non-cancer indications; novel Antibody display, selection and screening technologies; novel checkpoint modulators / immuno-oncology; Engineering antibodies for T-cell therapy; novel Engineering strategies to enhance Antibody functions; and the biological Impact of Fc receptor engagement. The meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will review progress toward a neutralizing Antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies; and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab for multiple myeloma. In a featured presentation, a representative of the World Health Organization's INN expert group will provide a perspective on Antibody naming. "Antibodies to watch in 2017" and progress on The Antibody Society's 2016 initiatives will be presented during the Society's special session. In addition, two pre-conference workshops covering ways to accelerate Antibody drugs to the clinic and the applications of next-generation sequencing in Antibody discovery and Engineering will be held on Sunday December 11, 2016.

  • Antibody Engineering therapeutics 2016 the Antibody society s annual meeting december 11 15 2016 san diego ca
    mAbs, 2015
    Co-Authors: James W Larrick, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Dennis R. Burton, Jamie K. Scott, Mark R Alfenito, Cynthia A. Lemere, Anne Messer, Paul Carter
    Abstract:

    Antibody Engineering & Therapeutics, the largest meeting devoted to Antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and future Antibody therapeutics development. Session topics include bispecifics and designer polyclonal antibodies; antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy; antibodies for non-cancer indications; novel Antibody display, selection and screening technologies; novel checkpoint modulators / immuno-oncology; Engineering antibodies for T-cell therapy; novel Engineering strategies to enhance Antibody functions; and the biological Impact of Fc receptor engagement. The meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will review progress toward a neutralizing Antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies; and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab for multiple myeloma. In a featured presentation, a representative of the World Health Organization's INN expert group will provide a perspective on Antibody naming. "Antibodies to watch in 2017" and progress on The Antibody Society's 2016 initiatives will be presented during the Society's special session. In addition, two pre-conference workshops covering ways to accelerate Antibody drugs to the clinic and the applications of next-generation sequencing in Antibody discovery and Engineering will be held on Sunday December 11, 2016.

  • Antibody Engineering and Therapeutics Conference: The Annual Meeting of the Antibody Society, December 8–12, 2013, Huntington Beach, CA
    mAbs, 2014
    Co-Authors: Juan Almagro, Gary L. Gilliland, Janice M Reichert, Matthias Pauthner, Felix Breden, Jamie K. Scott, Devin Sok, Gustavo Helguera, Raiees Andrabi, Robert Mabry
    Abstract:

    The 24th Antibody Engineering & Therapeutics meeting brought together a broad range of participants who were updated on the latest advances in Antibody research and development. Organized by IBC Life Sciences, the gathering is the annual meeting of The Antibody Society, which serves as the scientific sponsor. Preconference workshops on 3D modeling and delineation of clonal lineages were featured, and the conference included sessions on a wide variety of topics relevant to researchers, including systems biology; Antibody deep sequencing and repertoires; the effects of Antibody gene variation and usage on Antibody response; directed evolution; knowledge-based design; antibodies in a complex environment; polyreactive antibodies and polyspecificity; the interface between Antibody therapy and cellular immunity in cancer; antibodies in cardiometabolic medicine; Antibody pharmacokinetics, distribution and off-target toxicity; optimizing Antibody formats for immunotherapy; polyclonals, oligoclonals and bispecifics; Antibody discovery platforms; and Antibody-drug conjugates.

  • Antibody Engineering and therapeutics conference the annual meeting of the Antibody society december 8 12 2013 huntington beach ca
    mAbs, 2013
    Co-Authors: Juan Almagro, Gary L. Gilliland, Janice M Reichert, Matthias Pauthner, Felix Breden, Jamie K. Scott, Devin Sok, Gustavo Helguera, Raiees Andrabi, Robert Mabry
    Abstract:

    The 24th Antibody Engineering & Therapeutics meeting brought together a broad range of participants who were updated on the latest advances in Antibody research and development. Organized by IBC Life Sciences, the gathering is the annual meeting of The Antibody Society, which serves as the scientific sponsor. Preconference workshops on 3D modeling and delineation of clonal lineages were featured, and the conference included sessions on a wide variety of topics relevant to researchers, including systems biology; Antibody deep sequencing and repertoires; the effects of Antibody gene variation and usage on Antibody response; directed evolution; knowledge-based design; antibodies in a complex environment; polyreactive antibodies and polyspecificity; the interface between Antibody therapy and cellular immunity in cancer; antibodies in cardiometabolic medicine; Antibody pharmacokinetics, distribution and off-target toxicity; optimizing Antibody formats for immunotherapy; polyclonals, oligoclonals and bispecifics; Antibody discovery platforms; and Antibody-drug conjugates.

James W Larrick - One of the best experts on this subject based on the ideXlab platform.

  • Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    mAbs, 2015
    Co-Authors: Paul W. H. I. Parren, Andrew Bradbury, James W Larrick, James S. Huston, Kerry A. Chester, Dennis R. Burton, Paul J Carter, Trudi Veldman, Mark R Alfenito, Jamie K. Scott
    Abstract:

    Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, will be held in San Diego, CA in early December 2015. In this meeting preview, the chairs provide their thoughts on the importance of their session topics, which include Antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in Antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, Antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, overcoming resistance to clinical immunotherapy, and building comprehensive IGVH-gene repertoires through discovering, confirming and cataloging new germline IGVH genes. The Antibody Society's special session will focus on "Antibodies to watch" in 2016, which are a subset of the nearly 50 antibodies currently in Phase 3 clinical studies. Featuring over 100 speakers in total, the meeting will commence with keynote presentations by Erica Ollmann Saphire (The Scripps Research Institute), Wayne A. Marasco (Dana-Farber Cancer Institute/Harvard Medical School), Joe W. Gray (Oregon Health & Science University), and Anna M. Wu (University of California Los Angeles), and it will conclude with workshops on the promise and challenges of using next-generation sequencing for Antibody discovery and Engineering from synthetic and in vivo libraries and on computational Antibody design.

  • Antibody Engineering & Therapeutics 2016: The Antibody Society's Annual Meeting, December 11-15, 2016, San Diego, CA
    mAbs, 2015
    Co-Authors: James W Larrick, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Dennis R. Burton, Jamie K. Scott, Mark R Alfenito, Cynthia A. Lemere, Anne Messer, Paul Carter
    Abstract:

    Antibody Engineering & Therapeutics, the largest meeting devoted to Antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and future Antibody therapeutics development. Session topics include bispecifics and designer polyclonal antibodies; antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy; antibodies for non-cancer indications; novel Antibody display, selection and screening technologies; novel checkpoint modulators / immuno-oncology; Engineering antibodies for T-cell therapy; novel Engineering strategies to enhance Antibody functions; and the biological Impact of Fc receptor engagement. The meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will review progress toward a neutralizing Antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies; and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab for multiple myeloma. In a featured presentation, a representative of the World Health Organization's INN expert group will provide a perspective on Antibody naming. "Antibodies to watch in 2017" and progress on The Antibody Society's 2016 initiatives will be presented during the Society's special session. In addition, two pre-conference workshops covering ways to accelerate Antibody drugs to the clinic and the applications of next-generation sequencing in Antibody discovery and Engineering will be held on Sunday December 11, 2016.

  • Antibody Engineering therapeutics 2016 the Antibody society s annual meeting december 11 15 2016 san diego ca
    mAbs, 2015
    Co-Authors: James W Larrick, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Dennis R. Burton, Jamie K. Scott, Mark R Alfenito, Cynthia A. Lemere, Anne Messer, Paul Carter
    Abstract:

    Antibody Engineering & Therapeutics, the largest meeting devoted to Antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and future Antibody therapeutics development. Session topics include bispecifics and designer polyclonal antibodies; antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy; antibodies for non-cancer indications; novel Antibody display, selection and screening technologies; novel checkpoint modulators / immuno-oncology; Engineering antibodies for T-cell therapy; novel Engineering strategies to enhance Antibody functions; and the biological Impact of Fc receptor engagement. The meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will review progress toward a neutralizing Antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies; and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab for multiple myeloma. In a featured presentation, a representative of the World Health Organization's INN expert group will provide a perspective on Antibody naming. "Antibodies to watch in 2017" and progress on The Antibody Society's 2016 initiatives will be presented during the Society's special session. In addition, two pre-conference workshops covering ways to accelerate Antibody drugs to the clinic and the applications of next-generation sequencing in Antibody discovery and Engineering will be held on Sunday December 11, 2016.

  • Antibody Engineering and therapeutics conference The annual meeting of the Antibody society, Huntington Beach, CA, December 7-11, 2014
    mAbs, 2014
    Co-Authors: James W Larrick, Gregory P. Adams, Andreas Plückthun, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Ian M. Tomlinson, Kerry A. Chester, Dennis R. Burton, Louis M. Weiner
    Abstract:

    The 25th anniversary of the Antibody Engineering & Therapeutics Conference, the Annual Meeting of The Antibody Society, will be held in Huntington Beach, CA, December 7-11, 2014. Organized by IBC Life Sciences, the event will celebrate past successes, educate participants on current activities and offer a vision of future progress in the field. Keynote addresses will be given by academic and industry experts Douglas Lauffenburger (Massachusetts Institute of Technology), Ira Pastan (National Cancer Institute), James Wells (University of California, San Francisco), Ian Tomlinson (GlaxoSmithKline) and Anthony Rees (Rees Consulting AB and Emeritus Professor, University of Bath). These speakers will provide updates of their work, placed in the context of the substantial growth of the industry over the past 25 years.

  • Antibody Engineering at the millennium.
    BioTechniques, 2000
    Co-Authors: Jorge V. Gavilondo, James W Larrick
    Abstract:

    It has been almost 100 years since von Behring and Kitasato received the first Nobel prize for the discovery of passive immunotherapy and nearly 25 years since Kohler and Milstein first reported hy...

Richard H J Begent - One of the best experts on this subject based on the ideXlab platform.

  • IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.
    mAbs, 2013
    Co-Authors: Peter-christian Klöhn, Ulrich Wuellner, Nora Zizlsperger, Yu Zhou, Daniel Tavares, Sven Berger, Kirstin A Zettlitz, Gabriele Proetzel, May Yong, Richard H J Begent
    Abstract:

    The 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences, and the 2012 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 3-6, 2012 in San Diego, CA. The meeting drew over 800 participants who attended sessions on a wide variety of topics relevant to Antibody research and development. As a prelude to the main events, a pre-conference workshop held on December 2, 2012 focused on intellectual property issues that impact Antibody Engineering. The Antibody Engineering Conference was composed of six sessions held December 3-5, 2012: (1) From Receptor Biology to Therapy; (2) Antibodies in a Complex Environment; (3) Antibody Targeted CNS Therapy: Beyond the Blood Brain Barrier; (4) Deep Sequencing in B Cell Biology and Antibody Libraries; (5) Systems Medicine in the Development of Antibody Therapies/Systematic Validation of Novel Antibody Targets; and (6) Antibody Activity and Animal Models. The Antibody Therapeutics conference comprised four sessions held December 4-5, 2012: (1) Clinical and Preclinical Updates of Antibody-Drug Conjugates; (2) Multifunctional Antibodies and Antibody Combinations: Clinical Focus; (3) Development Status of Immunomodulatory Therapeutic Antibodies; and (4) Modulating the Half-Life of Antibody Therapeutics. The Antibody Society's special session on applications for recording and sharing data based on GIATE was held on December 5, 2012, and the conferences concluded with two combined sessions on December 5-6, 2012: (1) Development Status of Early Stage Therapeutic Antibodies; and (2) Immunomodulatory Antibodies for Cancer Therapy.

  • IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.
    mAbs, 2012
    Co-Authors: John Marquardt, Janice M Reichert, Andrew Bradbury, Richard H J Begent, James S. Huston, Kerry A. Chester, Jamie K. Scott, Trudi Veldman, Philip E. Thorpe, Louis M. Weiner
    Abstract:

    Now in its 23rd and 10th years, respectively, the Antibody Engineering and Antibody Therapeutics conferences are the Annual Meeting of The Antibody Society. The scientific program covers the full spectrum of challenges in Antibody research and development from basic science through clinical development. In this preview of the conferences, the chairs provide their thoughts on sessions that will allow participants to track emerging trends in (1) the development of next-generation immunomodulatory antibodies; (2) the complexity of the environment in which antibodies must function; (3) Antibody-targeted central nervous system (CNS) therapies that cross the blood brain barrier; (4) the extension of Antibody half-life for improved efficacy and pharmacokinetics (PK)/pharmacodynamics (PD); and (5) the application of next generation DNA sequencing to accelerate Antibody research. A pre-conference workshop on Sunday, December 2, 2012 will update participants on recent intellectual property (IP) law changes that affect Antibody research, including biosimilar legislation, the America Invents Act and recent court cases. Keynote presentations will be given by Andreas Plückthun (University of Zürich), who will speak on Engineering receptor ligands with powerful cellular responses; Gregory Friberg (Amgen Inc.), who will provide clinical updates of bispecific antibodies; James D. Marks (University of California, San Francisco), who will discuss a systems approach to generating tumor targeting antibodies; Dario Neri (Swiss Federal Institute of Technology Zürich), who will speak about delivering immune modulators at the sites of disease; William M. Pardridge (University of California, Los Angeles), who will discuss delivery across the blood-brain barrier; and Peter Senter (Seattle Genetics, Inc.), who will present his vision for the future of Antibody-drug conjugates. For more information on these meetings or to register to attend, please visit www.IBCLifeSciences.com/AntibodyEng or call 800-390-4078. Members of The Antibody Society and mAbs journal subscribers receive a 20% discount for meeting registration. To obtain this discount, email kdostie@ibcusa.com. mAbs is the official therapeutics journal of The Antibody Society and offers a discounted subscription to Society members for $49.

  • IBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3–6, 2012, San Diego, CA
    mAbs, 2012
    Co-Authors: Peter-christian Klöhn, Ulrich Wuellner, Nora Zizlsperger, Yu Zhou, Daniel Tavares, Sven Berger, Kirstin A Zettlitz, Gabriele Proetzel, May Yong, Richard H J Begent
    Abstract:

    The 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics international conferences, and the 2011 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5-8, 2011 in San Diego, CA. The meeting drew ~800 participants who attended sessions on a wide variety of topics relevant to Antibody research and development. As a preview to the main events, a pre-conference workshop held on December 4, 2011 focused on antibodies as probes of structure. The Antibody Engineering Conference comprised eight sessions: (1) structure and dynamics of antibodies and their membrane receptor targets; (2) model-guided generation of binding sites; (3) novel selection strategies; (4) antibodies in a complex environment: targeting intracellular and misfolded proteins; (5) rational vaccine design; (6) viral retargeting with engineered binding molecules; (7) the biology behind potential blockbuster antibodies and (8) antibodies as signaling modifiers: where did we go right, and can we learn from success? The Antibody Therapeutics session comprised five sessions: (1)Twenty-five years of therapeutic antibodies: lessons learned and future challenges; (2) preclinical and early stage development of Antibody therapeutics; (3) next generation anti-angiogenics; (4) updates of clinical stage Antibody therapeutics and (5) Antibody drug conjugates and bispecific antibodies.

Andrew Bradbury - One of the best experts on this subject based on the ideXlab platform.

  • Antibody Engineering & therapeutics, the annual meeting of the Antibody society December 7–10, 2015, San Diego, CA, USA
    mAbs, 2016
    Co-Authors: Matthias Pauthner, Thierry Wurch, Janice M Reichert, Jenny Yeung, Chris Ullman, Joost Bakker, Fridtjof Lund-johansen, Andrew Bradbury, Paul Carter, Joost P.m. Melis
    Abstract:

    The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015. The latest innovations and advances in Antibody research and development were discussed, covering a myriad of Antibody-related topics by more than 100 speakers, who were carefully selected by The Antibody Society. As a prelude, attendees could join the pre-conference training course focusing, among others, on the Engineering and enhancement of antibodies and Antibody-like scaffolds, bispecific Antibody Engineering and adaptation to generate chimeric antigen receptor constructs. The main event covered 4 d of scientific sessions that included Antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in Antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, Antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, building comprehensive IgVH-gene repertoires through discovering, confirming and cataloging new germline IgVH genes, and overcoming resistance to clinical immunotherapy. The Antibody Society's special session focused on "Antibodies to watch" in 2016. Another special session put the spotlight on the limitations of the new definitions for the assignment of Antibody international nonproprietary names introduced by the World Health Organization. The convention concluded with workshops on computational Antibody design and on the promise and challenges of using next-generation sequencing for Antibody discovery and Engineering from synthetic and in vivo libraries.

  • Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    mAbs, 2015
    Co-Authors: Paul W. H. I. Parren, Andrew Bradbury, James W Larrick, James S. Huston, Kerry A. Chester, Dennis R. Burton, Paul J Carter, Trudi Veldman, Mark R Alfenito, Jamie K. Scott
    Abstract:

    Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, will be held in San Diego, CA in early December 2015. In this meeting preview, the chairs provide their thoughts on the importance of their session topics, which include Antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in Antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, Antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, overcoming resistance to clinical immunotherapy, and building comprehensive IGVH-gene repertoires through discovering, confirming and cataloging new germline IGVH genes. The Antibody Society's special session will focus on "Antibodies to watch" in 2016, which are a subset of the nearly 50 antibodies currently in Phase 3 clinical studies. Featuring over 100 speakers in total, the meeting will commence with keynote presentations by Erica Ollmann Saphire (The Scripps Research Institute), Wayne A. Marasco (Dana-Farber Cancer Institute/Harvard Medical School), Joe W. Gray (Oregon Health & Science University), and Anna M. Wu (University of California Los Angeles), and it will conclude with workshops on the promise and challenges of using next-generation sequencing for Antibody discovery and Engineering from synthetic and in vivo libraries and on computational Antibody design.

  • Antibody Engineering & Therapeutics 2016: The Antibody Society's Annual Meeting, December 11-15, 2016, San Diego, CA
    mAbs, 2015
    Co-Authors: James W Larrick, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Dennis R. Burton, Jamie K. Scott, Mark R Alfenito, Cynthia A. Lemere, Anne Messer, Paul Carter
    Abstract:

    Antibody Engineering & Therapeutics, the largest meeting devoted to Antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and future Antibody therapeutics development. Session topics include bispecifics and designer polyclonal antibodies; antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy; antibodies for non-cancer indications; novel Antibody display, selection and screening technologies; novel checkpoint modulators / immuno-oncology; Engineering antibodies for T-cell therapy; novel Engineering strategies to enhance Antibody functions; and the biological Impact of Fc receptor engagement. The meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will review progress toward a neutralizing Antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies; and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab for multiple myeloma. In a featured presentation, a representative of the World Health Organization's INN expert group will provide a perspective on Antibody naming. "Antibodies to watch in 2017" and progress on The Antibody Society's 2016 initiatives will be presented during the Society's special session. In addition, two pre-conference workshops covering ways to accelerate Antibody drugs to the clinic and the applications of next-generation sequencing in Antibody discovery and Engineering will be held on Sunday December 11, 2016.

  • Antibody Engineering therapeutics 2016 the Antibody society s annual meeting december 11 15 2016 san diego ca
    mAbs, 2015
    Co-Authors: James W Larrick, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Dennis R. Burton, Jamie K. Scott, Mark R Alfenito, Cynthia A. Lemere, Anne Messer, Paul Carter
    Abstract:

    Antibody Engineering & Therapeutics, the largest meeting devoted to Antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and future Antibody therapeutics development. Session topics include bispecifics and designer polyclonal antibodies; antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy; antibodies for non-cancer indications; novel Antibody display, selection and screening technologies; novel checkpoint modulators / immuno-oncology; Engineering antibodies for T-cell therapy; novel Engineering strategies to enhance Antibody functions; and the biological Impact of Fc receptor engagement. The meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will review progress toward a neutralizing Antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies; and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab for multiple myeloma. In a featured presentation, a representative of the World Health Organization's INN expert group will provide a perspective on Antibody naming. "Antibodies to watch in 2017" and progress on The Antibody Society's 2016 initiatives will be presented during the Society's special session. In addition, two pre-conference workshops covering ways to accelerate Antibody drugs to the clinic and the applications of next-generation sequencing in Antibody discovery and Engineering will be held on Sunday December 11, 2016.

  • Antibody Engineering and therapeutics conference The annual meeting of the Antibody society, Huntington Beach, CA, December 7-11, 2014
    mAbs, 2014
    Co-Authors: James W Larrick, Gregory P. Adams, Andreas Plückthun, Andrew Bradbury, Paul W. H. I. Parren, James S. Huston, Ian M. Tomlinson, Kerry A. Chester, Dennis R. Burton, Louis M. Weiner
    Abstract:

    The 25th anniversary of the Antibody Engineering & Therapeutics Conference, the Annual Meeting of The Antibody Society, will be held in Huntington Beach, CA, December 7-11, 2014. Organized by IBC Life Sciences, the event will celebrate past successes, educate participants on current activities and offer a vision of future progress in the field. Keynote addresses will be given by academic and industry experts Douglas Lauffenburger (Massachusetts Institute of Technology), Ira Pastan (National Cancer Institute), James Wells (University of California, San Francisco), Ian Tomlinson (GlaxoSmithKline) and Anthony Rees (Rees Consulting AB and Emeritus Professor, University of Bath). These speakers will provide updates of their work, placed in the context of the substantial growth of the industry over the past 25 years.